MedTrace Logo

DC-CIK Combined With TACE in the Treatment of Hepatocellular Carcinoma

NCT02487017 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2016-05-24

No results posted yet for this study

Summary

Evaluation of DC-CIK cells combined TACE treatment for HCC

Conditions

Interventions

PROCEDURE

Transcatheter Arterial Chemoembolization (TACE)

Transcatheter Arterial Chemoembolization (TACE): 5-FU 400mg/m2 Hepatic arterial infusion ,lipiodol amount is usually 20 ml,the perfusion time should not be less than 20 min

BIOLOGICAL

DC-CIK

Transcatheter Arterial Chemoembolization (TACE): 5-FU 400mg/m2 Hepatic arterial infusion ,lipiodol amount is usually 20 ml, the perfusion time should not be less than 20 min DC-CIK: 8×10\^9 DC-CIK cells for each infusion, IV (in the vein) for each infusion at least 3 cycles, each cycle received four infusions on day 14, 16, 30 and 32

Sponsors & Collaborators

  • Yantai City Hospital for Infectious Diseases

    collaborator UNKNOWN

  • Shenzhen Hornetcorn Bio-technology Company, LTD

    lead INDUSTRY

Principal Investigators

  • Xiangzhong Liu, Professor · Yantai City Hospital for Infectious Diseases Immunotherapy center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-05-31
Primary Completion
2018-12-31
Completion
2018-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02487017 on ClinicalTrials.gov